| 4AB Stock | | | EUR 167.00 0.02 0.01% |
President
Mr. Robert A. Michael serves as Chief Financial Officer, Senior Vice President of the Company. Mr. Michael was AbbVies Vice President, Controller, since March 1, 2017 and served as AbbVies Vice President, Treasurer from 2015 to 2016, and as Vice President, Controller, Commercial Operations from 2013 to 2015. He joined Abbott Laboratories in 1993 and held numerous positions in the finance organization. since 2018.
| Age | 53 |
| Tenure | 6 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset
(ROA) of
0.0991 % which means that it generated a profit of $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.7239 %, meaning that it generated $0.7239 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.
AbbVie Inc has accumulated 59.13
B in total debt. AbbVie Inc has a current ratio of 1.02, suggesting that it
is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist AbbVie until it has trouble settling it off, either with new capital or with free cash flow. So, AbbVie's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AbbVie Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AbbVie to invest in growth at high rates of return. When we think about AbbVie's use of debt, we should always consider it together with cash and equity.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. ABBVIE INC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 30000 people. AbbVie Inc (4AB) is traded on Frankfurt Exchange in Germany and employs 50,000 people.
Management Performance
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Gonzalez, Chairman of the Board, CEO | |
| Perry Siatis, Gen VP | |
| Thomas Hudson, VP Officer | |
| Timothy Richmond, Senior Vice President - Human Resources | |
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | |
| Robert Michael, Vice President Controller | |
| Elizabeth Shea, VP Relations | |
| Azita SalekiGerhardt, Senior Vice President - Operations | |
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | |
| Scott Reents, VP CFO | |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in AbbVie Stock
When determining whether AbbVie Inc is a strong investment it is important to analyze AbbVie's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AbbVie's
future performance.
For an informed investment choice regarding AbbVie Stock, refer to the following important reports: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.